BPG is committed to discovery and dissemination of knowledge
Featured Articles
1/11/2024 7:53:02 AM | Browse: 503 | Download: 1109
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 89098
Country China
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Editorial
Article Title Present situation and prospect of immunotherapy for unresectable locally advanced esophageal cancer during peri-radiotherapy
Manuscript Source Invited Manuscript
All Author List Feng-Mei Wang, Peng Mo, Xue Yan, Xin-Yue Lin and Zhi-Chao Fu
Funding Agency and Grant Number
Funding Agency Grant Number
Natural Science Foundation of Fujian Province No. 2021J011259
Corresponding Author Zhi-Chao Fu, MD, PhD, Doctor, Doctor, Department of Radiotherapy, Fuzong Clinical Medical College (900th Hospital), Fujian Medical University, No. 156 West Second Ring Road North, Fuzhou 350025, Fujian Province, China. fauster1112@126.com
Key Words Esophageal carcinoma; Locally advanced; Radiotherapy; Immunotherapy
Core Tip For unresectable or inoperable non-metastatic esophageal cancer, concurrent radiotherapy and chemotherapy is the standard treatment recommended by various guidelines. Because its curative effect is still not ideal, it is still necessary to explore radical radiotherapy and chemotherapy in the future, and it is considered to be very promising to combine with immune drugs represented by anti-programmed death protein-1. This paper mainly discusses how to combine radical concurrent radiotherapy and chemotherapy with immunotherapy for unresectable local late esophageal cancer.
Publish Date 2024-01-11 06:17
Citation Wang FM, Mo P, Yan X, Lin XY, Fu ZC. Present situation and prospect of immunotherapy for unresectable locally advanced esophageal cancer during peri-radiotherapy. World J Gastrointest Oncol 2024; 16(1): 1-7
URL https://www.wjgnet.com/1948-5204/full/v16/i1/1.htm
DOI https://dx.doi.org/10.4251/wjgo.v16.i1.1
Full Article (PDF) WJGO-16-1-with-cover.pdf
Full Article (Word) WJGO-16-1.docx